Danish Lung Cancer Group
6
1
2
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy
Role: collaborator
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
Role: lead
Intensified Follow-up of Lung Cancer Using Weekly Questionnaires Via the Internet
Role: collaborator
Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients
Role: collaborator
Chronic Pain After Thoracotomy, an Incidence Study
Role: collaborator
Danish Lung Cancer Screening Trial (DLCST)
Role: lead
All 6 trials loaded